Sagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It operates through two segments: Sagent US, consisting of the Company's operations in the United States and the Sagent (China) Pharmaceuticals Co. Ltd. (SCP) manufacturing facility, and Omega, which is focused on the Canadian and international markets. It offers a range of products across anti-infective, oncology and critical care indications in a range of presentations, including single and multi-dose vials, pre-filled ready-to-use syringes and premix bags. Its Sagent US product portfolio includes approximately 60 marketed products that it offers in over 180 presentations, and its Omega segment offers over 50 products.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:SGNT
- CUSIP: 78669210
- Web: www.sagentpharma.com/
Average Prices:- 50 Day Moving Avg: $21.72
- 200 Day Moving Avg: $15.37
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 29.77
- P/E Growth: 0.00
Profitability:- Net Margins: -0.72%
- Return on Equity: -0.81%
- Return on Assets: -0.59%
Misc:
Frequently Asked Questions for Sagent Pharmaceuticals (NASDAQ:SGNT)
What is Sagent Pharmaceuticals' stock symbol?
Sagent Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGNT."
How were Sagent Pharmaceuticals' earnings last quarter?
Sagent Pharmaceuticals Inc (NASDAQ:SGNT) posted its quarterly earnings data on Tuesday, May, 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.01 by $0.16. The firm earned $67.30 million during the quarter, compared to analyst estimates of $74.30 million. Sagent Pharmaceuticals had a negative return on equity of 0.81% and a negative net margin of 0.72%. The company's quarterly revenue was down 17.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.04 earnings per share. View Sagent Pharmaceuticals' Earnings History.
Who are some of Sagent Pharmaceuticals' key competitors?
Some companies that are related to Sagent Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis AG (NVS), Merck & Company (MRK), Novo Nordisk A/S (NVO), Sanofi (SNY), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Eli Lilly and Company (LLY), Abbott Laboratories (ABT), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Ltd (TEVA), Dr. Reddy's Laboratories Ltd (RDY) and Patheon NV (PTHN).
How do I buy Sagent Pharmaceuticals stock?
Shares of Sagent Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sagent Pharmaceuticals' stock price today?
One share of Sagent Pharmaceuticals stock can currently be purchased for approximately $21.73.
MarketBeat Community Rating for Sagent Pharmaceuticals (NASDAQ SGNT)MarketBeat's community ratings are surveys of what our community members think about Sagent Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Sagent Pharmaceuticals (NASDAQ:SGNT) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Sagent Pharmaceuticals (NASDAQ:SGNT)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/11/2016 | Deutsche Bank AG | Downgrade | Buy -> Hold | | N/A |  |
| 7/12/2016 | Raymond James Financial, Inc. | Downgrade | Buy -> Market Perform | | N/A | |
| 7/11/2016 | Royal Bank Of Canada | Downgrade | Outperform -> Hold | | N/A | |
| 7/11/2016 | Piper Jaffray Companies | Downgrade | Overweight -> Neutral | $22.00 -> $21.75 | N/A | |
| 6/17/2016 | Jefferies Group LLC | Reiterated Rating | Hold | $13.00 -> $15.00 | N/A | |
| 6/1/2016 | J P Morgan Chase & Co | Reiterated Rating | Neutral | | N/A | |
| 5/9/2016 | Bank of America Corporation | Reiterated Rating | Hold | $13.00 | N/A | |
(Data available from 9/22/2015 forward)
Earnings History for Sagent Pharmaceuticals (NASDAQ:SGNT)Earnings History by Quarter for Sagent Pharmaceuticals (NASDAQ SGNT)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/3/2016 | Q1 | $0.01 | ($0.15) | $74.30 million | $67.30 million | View | N/A | |
| 2/16/2016 | Q415 | ($0.02) | ($0.55) | $78.13 million | $83.10 million | View | Listen | |
| 11/3/2015 | Q315 | ($0.07) | $0.01 | $73.84 million | $75.20 million | View | N/A | |
| 8/4/2015 | Q215 | $0.05 | ($0.01) | $83.28 million | $77.30 million | View | N/A | |
| 5/5/2015 | Q115 | $0.04 | $0.04 | $80.63 million | $82.60 million | View | N/A | |
| 2/19/2015 | Q414 | $0.01 | $0.91 | $76.20 million | $84.40 million | View | N/A | |
| 11/4/2014 | Q314 | ($0.04) | $0.08 | $64.01 million | $65.40 million | View | N/A | |
| 7/30/2014 | Q214 | ($0.01) | $0.09 | $67.14 million | $69.20 million | View | Listen | |
| 5/6/2014 | Q114 | ($0.02) | $0.16 | $65.66 million | $70.90 million | View | Listen | |
| 2/11/2014 | Q4 | ($0.01) | $0.11 | $60.25 million | $64.10 million | View | Listen | |
| 11/5/2013 | | ($0.03) | $0.10 | | | View | N/A | |
| 8/6/2013 | Q2 2013 | | $0.46 | $59.27 million | $59.60 million | View | N/A | |
| 5/6/2013 | Q1 2013 | ($0.03) | $0.34 | $55.31 million | $60.20 million | View | N/A | |
| 11/8/2012 | Q312 | ($0.20) | ($0.13) | $48.60 million | $49.40 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Sagent Pharmaceuticals (NASDAQ:SGNT)Current Year EPS Consensus Estimate: $0.24 EPS
Next Year EPS Consensus Estimate: $0.73 EPS
Dividend History for Sagent Pharmaceuticals (NASDAQ:SGNT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Sagent Pharmaceuticals (NASDAQ:SGNT)Insider Trades by Quarter for Sagent Pharmaceuticals (NASDAQ:SGNT)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 4/21/2016 | Ventures Fund V L.P. Vivo | Major Shareholder | Sell | 2,005 | $13.55 | $27,167.75 | |
| 11/4/2015 | Ventures Fund V L.P. Vivo | Major Shareholder | Sell | 603,177 | $15.72 | $9,481,942.44 | |
| 11/3/2015 | Vivo Ventures Vi, Llc | Major Shareholder | Sell | 67,283 | $16.32 | $1,098,058.56 | |
| 11/2/2015 | Vivo Ventures Vi, Llc | Major Shareholder | Sell | 93,523 | $16.87 | $1,577,733.01 | |
| 1/27/2015 | Morgan Stanley Investment Mana | Major Shareholder | Sell | 78,041 | $26.16 | $2,041,552.56 | |
| 1/23/2015 | Morgan Stanley Investment Mana | Major Shareholder | Sell | 211,883 | $25.61 | $5,426,323.63 | |
| 1/21/2015 | Morgan Stanley Investment Mana | Major Shareholder | Sell | 69,316 | $25.23 | $1,748,842.68 | |
| 1/16/2015 | Morgan Stanley Investment Mana | Major Shareholder | Sell | 125,000 | $25.16 | $3,145,000.00 | |
| 1/14/2015 | Morgan Stanley Investment Mana | Major Shareholder | Sell | 100,000 | $25.51 | $2,551,000.00 | |
| 10/8/2014 | Robert J Flanagan | Director | Sell | 16,000 | $31.56 | $504,960.00 | |
| 10/7/2014 | Robert J Flanagan | Director | Sell | 8,000 | $31.15 | $249,200.00 | |
| 9/25/2014 | Robert J Flanagan | Director | Sell | 16,000 | $30.01 | $480,160.00 | |
| 9/24/2014 | Robert J Flanagan | Director | Sell | 8,000 | $30.30 | $242,400.00 | |
| 9/12/2014 | Robert J Flanagan | Director | Sell | 16,000 | $28.30 | $452,800.00 | |
| 9/11/2014 | Robert J Flanagan | Director | Sell | 8,000 | $28.35 | $226,800.00 | |
| 8/28/2014 | Robert J Flanagan | Director | Sell | 16,000 | $27.19 | $435,040.00 | |
| 8/27/2014 | Robert J Flanagan | Director | Sell | 8,000 | $27.30 | $218,400.00 | |
| 8/12/2014 | Robert J Flanagan | Director | Sell | 16,000 | $24.39 | $390,240.00 | |
| 7/31/2014 | Robert J Flanagan | Director | Sell | 16,000 | $25.60 | $409,600.00 | |
| 7/18/2014 | Robert J Flanagan | Director | Sell | 16,000 | $26.18 | $418,880.00 | |
| 7/2/2014 | Robert J Flanagan | Director | Sell | 16,000 | $26.51 | $424,160.00 | |
| 6/18/2014 | Robert J Flanagan | Director | Sell | 16,000 | $23.37 | $373,920.00 | |
| 6/4/2014 | Robert J Flanagan | Director | Sell | 16,000 | $22.17 | $354,720.00 | |
| 5/22/2014 | Robert Flanagan | Director | Sell | 8,000 | $22.02 | $176,160.00 | |
| 2/27/2014 | Michael Logerfo | Insider | Sell | 2,021 | $21.43 | $43,310.03 | |
| 10/3/2013 | Morgan Stanley Investment Mana | major shareholder | Sell | 47,826 | $20.27 | $969,433.02 | |
| 9/26/2013 | Morgan Stanley Investment Mana | major shareholder | Sell | 67,965 | $20.37 | $1,384,447.05 | |
| 9/25/2013 | Morgan Stanley Investment Mana | major shareholder | Sell | 48,124 | $21.30 | $1,025,041.20 | |
| 9/23/2013 | Morgan Stanley Investment Mana | major shareholder | Sell | 119,557 | $21.83 | $2,609,929.31 | |
| 9/19/2013 | Morgan Stanley Investment Mana | major shareholder | Sell | 88,885 | $22.53 | $2,002,579.05 | |
| 9/16/2013 | Frank Kung | Director | Sell | 1,161,717 | $21.25 | $24,686,486.25 | |
| 9/16/2013 | Jeffrey Yordon | CEO | Sell | 85,813 | $20.03 | $1,718,834.39 | |
| 9/16/2013 | Vivo Ventures Vi, Llc | major shareholder | Sell | 622,700 | $21.25 | $13,232,375.00 | |
| 8/12/2013 | Lorin Drake | VP | Sell | 1,000 | $23.69 | $23,690.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Sagent Pharmaceuticals (NASDAQ:SGNT)
Latest Headlines for Sagent Pharmaceuticals (NASDAQ:SGNT)
| Source: |
|
| Date | Headline |
|---|
 | NWQ Bought 12 New Holdings in 2nd Quarter
finance.yahoo.com - September 16 at 7:00 PM |
 | Form 4 Sagent Pharmaceuticals, For: Aug 29 Filed by: Krizman Anthony
www.streetinsider.com - September 1 at 7:13 PM |
 | Nichi-Iko Pharmaceutical Co., Ltd.
www.thestreet.com - August 30 at 10:37 AM |
| Nichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the Outstanding Shares of Common Stock of Sagent Pharmaceuticals, Inc.
au.finance.yahoo.com - August 29 at 7:14 PM |
| SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delist
biz.yahoo.com - August 29 at 7:14 PM |
| SAGENT PHARMACEUTICALS, INC. Financials
finance.yahoo.com - August 16 at 7:30 PM |
| Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sagent Pharmaceuticals, Inc. (SGNT)
finance.yahoo.com - August 10 at 7:54 PM |
| Form SC TO-T/A Sagent Pharmaceuticals, Filed by: Shepard Vision, Inc.
www.streetinsider.com - August 9 at 7:41 PM |
| Nichi-Iko Pharmaceutical Co., Ltd. Announces Expiration of HSR Waiting Period for Proposed Acquisition of Sagent Pharmaceuticals, Inc.
au.finance.yahoo.com - August 9 at 10:37 AM |
| SAGENT PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - August 5 at 7:38 PM |
| Shepard Vision, Inc., a Wholly-Owned Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd, Commences All-Cash …
finance.yahoo.com - August 1 at 1:01 PM |
| INVESTOR ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Sagent Pharmaceuticals, Inc. Concerning the Sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd.
finance.yahoo.com - July 22 at 11:48 AM |
Sagent Pharmaceuticals (SGNT) Chart for Friday, September, 22, 2017
